Oct 23 (Reuters) – Bristol-Myers Squibb Company: * IZALONTAMAB BRENGITECAN (IZA-BREN) REDUCED RISK OF DISEASE PROGRESSION OR DEATH BY 59% VERSUS CHEMOTHERAPY IN PATIENTS WITH ADVANCED HR+/HER2- BREAST
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Marc Jones LONDON, Oct 23 (Reuters) - The rout in global tech shares eased…
* World tech share selloff eases in Asia and Europe * Oil prices at five-month…
By Sai Ishwarbharath B, Abhirami G and Haripriya Suresh BENGALURU, Oct 23 Reuters) - Infosys…
BEIJING, Oct 23 (Reuters) - China's National Energy Administration has called on the country's oil…
VIDEO SHOWS: ARGENTINA'S SOCCER LEGEND LIONEL MESSI AND US SINGER PATTI SMITH RECEIVE THE PRINCESS…
By Stephanie Kelly LONDON, Oct 23 (Reuters) - Oil prices rose on Friday, with Brent…